Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Top Cited Papers
- 26 November 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 95 (11), 1046-1057
- https://doi.org/10.1161/01.res.0000149165.99974.12
Abstract
Vascular calcification often occurs with advancing age, atherosclerosis, various metabolic disorders such as diabetes mellitus and end-stage renal disease, or in rare genetic diseases, leading to serious clinical consequences. Such mineralization can occur at various sites (cardiac valves, arterial intima or media, capillaries), involve localized or diffuse widespread calcification, and result from numerous causes that provoke active inflammatory and osteogenic processes or disordered mineral homeostasis. Although valuable research has defined many key factors and cell types involved, surprising new insights continue to arise that deepen our understanding and suggest novel research directions or strategies for clinical intervention in calcific vasculopathies. One emerging area in vascular biology involves the RANKL/RANK/OPG system, molecules of the tumor necrosis factor-related family recently discovered to be critical regulators of immune and skeletal biology. Evidence is accumulating that such signals may be expressed, regulated, and function in vascular physiology and pathology in unique ways to promote endothelial cell survival, angiogenesis, monocyte or endothelial cell recruitment, and smooth muscle cell osteogenesis and calcification. Concerted research efforts are greatly needed to understand these potential roles, clarify whether RANKL (receptor activator of nuclear factor κB ligand) promotes and osteoprotegerin (OPG) protects against vascular calcification, define how OPG genetic polymorphisms relate to cardiovascular disease, and learn whether elevated serum OPG levels reflect endothelial dysfunction in patients. Overall, the RANKL/RANK/OPG system may mediate important and complex links between the vascular, skeletal, and immune systems. Thus, these molecules may play a central role in regulating the development of vascular calcification coincident with declines in skeletal mineralization with age, osteoporosis, or disease.Keywords
This publication has 81 references indexed in Scilit:
- Endothelial Cells Modulate Osteogenesis in Calcifying Vascular CellsJournal of Vascular Research, 2004
- Multilineage Potential of Cells From the Artery WallCirculation, 2003
- Mineral Exploration: Search for the Mechanism of Vascular Calcification and BeyondArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Bone Morphogenic Protein 4 Produced in Endothelial Cells by Oscillatory Shear Stress Stimulates an Inflammatory ResponseJournal of Biological Chemistry, 2003
- Stromal Cell-Derived Factor-1 (SDF-1) Recruits Osteoclast Precursors by Inducing Chemotaxis, Matrix Metalloproteinase-9 (MMP-9) Activity, and Collagen TransmigrationJournal of Bone and Mineral Research, 2003
- Increased expression of disintegrin‐metalloproteinases ADAM‐15 and ADAM‐9 following upregulation of integrins α5β1 and αvβ3 in atherosclerosisJournal of Cellular Biochemistry, 2003
- Inflammation in atherosclerosisNature, 2002
- The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical studyThe Journal of Pathology, 2001
- Effects of Immunosuppressants on Receptor Activator of NF-κB Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle CellsBiochemical and Biophysical Research Communications, 2001
- Activation of Peroxisome Proliferator-activated Receptor-γ Pathway Inhibits Osteoclast DifferentiationJournal of Biological Chemistry, 2000